Skip to main content
KZIA
NASDAQ Life Sciences

Kazia Therapeutics Appoints James Levine as CFO, Granting 200,000 ADS Options

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
8
Price
$12.87
Mkt Cap
$142.38M
52W Low
$3.544
52W High
$17.4
Market data snapshot near publication time

Summary

Kazia Therapeutics appointed James Levine, a seasoned biotech finance executive with a background in investment banking and CFO roles, as its new Chief Financial Officer, including a grant of 200,000 ADS options.


Key Events

  • New Chief Financial Officer Appointed

    James Levine has been appointed as Chief Financial Officer, effective June 1, 2026, bringing over two decades of experience.

  • Extensive Biotech Finance Experience

    Mr. Levine's background includes managing director roles at Goldman Sachs and CFO positions at clinical-stage oncology companies like Cardiff Oncology and Cidara Therapeutics, where he led significant financial structuring and collaborations.

  • Significant Equity Incentive

    He will receive options over 200,000 American Depositary Shares (ADSs), with one-third vesting upon commencement and the remainder vesting in equal yearly installments.

  • Strategic Fit for Growth

    His expertise in capital markets and strategic transactions is crucial as Kazia advances its pipeline and continues its capital raising efforts, following recent substantial offerings.


Analysis

Kazia Therapeutics has appointed James Levine as its new Chief Financial Officer. Mr. Levine brings extensive experience in investment banking and financial leadership at publicly traded biotech companies, including managing significant financial structuring and collaborations. This appointment is particularly important for a clinical-stage oncology company like Kazia, which has been actively engaged in capital raises and advancing its pipeline. The substantial equity grant of 200,000 ADS options aligns his interests with long-term shareholder value, signaling a strategic move to strengthen financial leadership.

At the time of this filing, KZIA was trading at $12.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $142.4M. The 52-week trading range was $3.54 to $17.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KZIA - Latest Insights

KZIA
Jun 02, 2026, 9:04 AM EDT
Filing Type: 424B3
Importance Score:
7
KZIA
Jun 02, 2026, 9:03 AM EDT
Filing Type: 424B3
Importance Score:
8
KZIA
Jun 02, 2026, 9:02 AM EDT
Filing Type: 424B3
Importance Score:
8
KZIA
Jun 02, 2026, 9:01 AM EDT
Filing Type: 424B3
Importance Score:
7
KZIA
Jun 02, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
8
KZIA
May 26, 2026, 8:03 AM EDT
Filing Type: 424B3
Importance Score:
7
KZIA
May 26, 2026, 8:02 AM EDT
Filing Type: 424B3
Importance Score:
9
KZIA
May 26, 2026, 8:01 AM EDT
Filing Type: 424B3
Importance Score:
8
KZIA
May 26, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
KZIA
May 26, 2026, 7:39 AM EDT
Source: Reuters
Importance Score:
7